Senores Pharmaceuticals Limited — Board Meeting, 23-07-2025: Outcome of Board Meeting

Senores Pharmaceuticals announced robust Q1 FY26 consolidated financial results. Total income surged 72% year-on-year to Rs 138 Cr, with Profit After Tax (PAT) nearly doubling by 95% to Rs 21 Cr. EBITDA saw a strong 60% growth, reaching Rs 34 Cr, reflecting solid operational performance. Revenue growth was significant in Regulated Markets (+69% to Rs 90 Cr) and Emerging Markets (+32% to Rs 29 Cr). The Board also approved the appointment of Mr. Jignesh Shashikant Desai as President-Finance. A substantial Rs 259 Cr from IPO proceeds remains unutilized and is currently parked in fixed deposits.